All In MedTech

Device Trial Radar · NCT02225392

Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma

Last checked: Nov 20, 2026Latest source record: Dec 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Apr 2014

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development; The Netherlands Asthma Foundation; Boston Scientific Corporation
First posted
Aug 26, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Approximately 5% of asthma patients suffer from severe asthma that is characterized by frequent asthma exacerbations resulting in significant morbidity and excessive utilisation of health care resources. Therefore, there is a strong need for improved therapeutic strategies for these patients. Insight in the pathogenesis and molecular pathways active in severe asthma is crucial to reach this goal. Bronchial Thermoplasty (BT) is a novel, innovative device-based treatment of severe asthma that is based on local, radiofrequent energy delivery in larger airways during bronchoscopy. Hypothesis: BT-induced clinical improvement in severe asthma is a consequence of reduction in airway smooth muscle (ASM) mass and (contractile/immunomodulatory) function, inflammation, neural innervation and/or vascular integrity resulting in altered airway remodelling. BT target identification and severe asthma phenotyping are critical for improved patient selection for BT and fundamental to discover novel, specific signalling pathways active in severe asthma.

Conditions

  • Asthma
  • Bronchial Asthma

Interventions

  • Bronchial thermoplastyProcedure

    Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.

  • Alair system (Boston Scientific, USA)Device

    The alair system consist of a controller and a bastket catheter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in airway smooth muscle (ASM) mass between immediate BT treated and the control group (N=20, randomized)Time frame: Baseline, week 25

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • University Medical Center Groningen

    Groningen, Netherlands

  • Academisch Medisch Centrum

    Amsterdam, North Holland, Netherlands

  • Royal Brompton Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.